Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
RNN > SEC Filings for RNN > Form 8-K on 30-Nov-2012All Recent SEC Filings

Show all filings for REXAHN PHARMACEUTICALS, INC.

Form 8-K for REXAHN PHARMACEUTICALS, INC.


30-Nov-2012

Entry into a Material Definitive Agreement, Other Events, Financial


ITEM 1.01 Entry Into a Material Definitive Agreement.

On November 29, 2012, Rexahn Pharmaceuticals, Inc. (the "Company"), Burill LLC and Maxim Group LLC (the "Underwriters"), entered into an underwriting agreement (the "Underwriting Agreement") to issue and sell 19,130,435 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), and common stock purchase warrants (the "Warrants") to purchase up to 10,521,739 shares of the Company's common stock (the "Offering"). The Common Stock and Warrants will be sold in units (the "Units"), with each Unit consisting of one share of Common Stock and a Warrant to purchase 0.55 shares of Common Stock at an exercise price of $0.472 per share of Common Stock. Each Unit will be sold to investors in this Offering at a negotiated price of $0.33 per unit. The shares of Common Stock and Warrants will be issued separately but can only be purchased together in this Offering. The Company has granted to the Underwriters an option to purchase up to 2,869,565 additional shares of Common Stock at a price of $0.32 per share and/or additional Warrants to purchase up to 1,578,261 shares of Common Stock at a price of $0.01 per Warrant. The option is exercisable, in whole or in part, for a period of 45 days from the date of the Prospectus Supplement.

The net proceeds are expected to be approximately $5.7 million, after deducting the underwriting discounts and commissions and estimated expenses payable by the Company, and without exercise of the Underwriters' over-allotment option.

The Underwriting Agreement contains customary representations, warranties, and agreements by the Company, and customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties, and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. These representations, warranties and covenants are not factual information to investors about the Company.

Pursuant to the Underwriting Agreement, directors and executive officers of the Company entered into agreements in substantially the form included as an exhibit to the Underwriting Agreement providing for a 90-day "lock-up" period with respect to sales of specified securities, subject to certain exceptions.

The offering is being made pursuant to the Registration Statement and Prospectus Supplement discussed below under Item 8.01. The Underwriting Agreement is filed as Exhibit 1.1 to this Current Report, and the description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Patton Boggs LLP relating to the legality of the issuance and sale of the shares and warrants in the offering is attached as Exhibit 5.1 hereto. On November 29, 2012, we issued a press release announcing that we had commenced and priced the offering. A copy of this press release is attached hereto as Exhibit 99.1.



Item 8.01 Other Events.

On November 30, 2012, the Company filed with the Securities Exchange Commission (the "Commission") a prospectus supplement (the "Prospectus Supplement") to the prospectus (the "Prospectus") included as part of the Company's registration statement on Form S-3 declared effective by the Commission on July 5, 2011 (File No. 333-175073) (the "Registration Statement"), pursuant to which the Company will issue, in an underwritten offering, 19,130,435 shares of the Company's Common Stock and Warrants to purchase up to 10,521,739 shares of the Company's common stock.

Prospective investors should read the Prospectus Supplement, the Prospectus and all documents incorporated by reference herein.




ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits.

         Exhibit                        Description
         1.1       Underwriting Agreement, dated November 29, 2012.
         4.1       Form of Underwriter Warrant.
         4.2       Form of Investor Warrant.
         5.1       Opinion of Patton Boggs LLP.
         23.1      Consent of Patton Boggs LLP (included in Exhibit 5.1).
         99.1      Press Release, dated November 29, 2012.


  Add RNN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for RNN - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.